Veriheal

APRIL 11, 2022

federal government is granting a handful of American companies the option to cultivate and study cannabis for medical research purposes. Groff North America is proud to be producing research-grade marijuana, so we can continue growing the field of cannabis-based medicine,” reads an official statement from the company’s website.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

Cannabis Law Report

NOVEMBER 1, 2021

Harvard Law School; Yale Law School; University of New Hampshire Franklin Pierce School of Law; Leiden Law School, Center for Law and Digital Technologies. Harvard Law School. Indigenous communities have used them for centuries, and researchers studied them in the 1950s and 60s. Mason Marks.

Research and Development 52

Research and Development Law Clinical Trials Therapy 52

Cannabis Law Report

MAY 29, 2022

is a Canadian company that researches, develops and grows psilocybin-producing mushrooms and functional mushrooms. The psilocybin mushrooms are headed to clinical trials, drug companies and medical facilities. “I’m Optimi Health Corp. Without that approval, using psilocybin is currently illegal.

Research and Development 52

Research and Development Clinical Trials Medicine Access 52

Cannabis Law Report

FEBRUARY 28, 2022

In the past two decades, pioneering research has rekindled interest in the therapeutic use of psychedelic substances such as psilocybin, ibogaine, and dimethyltryptamine (DMT). Indigenous communities have used them for centuries, and researchers studied them in the 1950s and ‘60s. Glenn Cohen & Mason Marks. 20 February 2022.

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

MMJ Recs

DECEMBER 17, 2023

Enacted in 2015, the program was designed to provide a narrow avenue for patients suffering from qualifying conditions to access low-THC cannabis under the supervision of qualified healthcare professionals. Current Texas Medical Marijuana Regulations CBD laws in Texas are governed by the Compassionate Use Program.

Law 52

Law Dispensary Clinical Trials Programs 52

Cannabis Law Report

JULY 6, 2021

This collaboration is intended to include research into COMP360 psilocybin therapy and other novel therapies that may be developed by COMPASS in areas of unmet need such as depression, post-traumatic stress disorder (PTSD) and anorexia.

Research and Development 98

Research and Development Clinical Trials Therapy Patients 98

Cannabis Law Report

JULY 1, 2021

The Project on Psychedelics Law and Regulation (POPLAR). The Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School is engaged in a three-year initiative to examine the ethical, legal, and social implications of psychedelics research, commerce, and therapeutics. Background.

Law 59

Law Policy Research and Development Clinical Trials 59

The Cannigma

JULY 1, 2022

Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. The cannabis research problem. Despite the massive amount of research publications that come out year over year, many of these studies face one or more research design limitations.

Research and Development 108

Research and Development Data THC Clinical Trials 108

MMJ Recs

MAY 9, 2024

As such, we provide you with a comprehensive guide for veterans using medical cannabis and the various aspects of it, including its usage, accessibility, legal considerations, healthcare options, and available resources. Navigating the complexities surrounding the Veterans Administration and medical cannabis can be daunting.

Research and Development 52

Research and Development Therapy Clinical Trials Treatment 52

Cannabis Law Report

MAY 29, 2022

Earlier this month, Senators Brian Schatz (D-HI) and Cory Booker (D-NJ) sent a letter to the National Institutes of Health (NIH) and the Food and Drug Administration (FDA) urging both agencies to advance research on the therapeutic effects of psychedelic drugs. [1] Recent Regulatory Developments. Challenges.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

DECEMBER 5, 2021

The Multidisciplinary Association for Psychedelic Studies (MAPS) and Vine Ventures have announced the creation of a novel, social impact Special Purpose Vehicle (SPV), called the Regenerative Financing Vine (RFV), that will infuse $70 million into patient access infrastructure and research for MDMA-assisted therapy for PTSD.

Therapy 52

Therapy Access Research and Development Clinical Trials 52

Cannabis Law Report

JANUARY 31, 2022

TSX-V:NUMI, OTC:LKYSF) said that its research facility– Numinus Bioscience– has been included on Health Canada’s list of federally licensed psilocybin producers. This list is available by request to those seeking access to psilocybin through the Special Access Program (SAP), and clinical researchers.

Research and Development 52

Research and Development Clinical Trials Packaging Access 52

Cannabis Law Report

NOVEMBER 23, 2021

. “If a small number of companies secure wide swaths of intellectual property early on, then the beneficial impact of that shift may be blunted,” warn researchers. Patents on Psychedelics: The Next Legal Battlefront of Drug Development. Harvard Law Review Forum, Vol. Harvard Law School. Mason Marks.

Law 52

Law Research and Development Therapy Clinical Trials 52

Cannabis Law Report

AUGUST 7, 2021

MAPS PBC catalyzes healing and well-being through psychedelic drug development, therapist training programs, and sales of prescription psychedelics. We are currently focused on developing MDMA-assisted therapy as a Breakthrough Therapy for PTSD, with plans to submit for FDA approval in 2023. European Regulatory Lead Executive Summary.

Clinical Trials 105

Clinical Trials Research and Development Compliance Compliance 105

The Cannigma

JUNE 14, 2021

For more than 50 years, if you wanted to do cannabis research in the United States, federal law said you had to get the cannabis from the University of Mississippi. We are absolutely ecstatic,” George Hodgin, the CEO of the Castroville, California based Biopharmaceutical Research Co. BRC) told The Cannigma this week.

DEA 133

DEA Research and Development Clinical Trials Pharmaceutical 133

Cannabis Law Report

SEPTEMBER 10, 2021

The announcement of a partnership between Clerkenwell Health and Octarine Bio signals a momentous time for the growth and development of the European psychedelic ecosystem. Clerkenwell Health is a psychedelic specialist clinical research organisation, based in the UK, backed with investment from VC Fund Vine Ventures, and Angel investors.

Research and Development 104

Research and Development Clinical Trials Therapy Environment 104

SpeedWeed

JULY 6, 2021

Harvard Law School is planning to open the first US policy center focused on the legalization and regulation of psychedelics like psilocybin, MDMA, and LSD. . This new program is being funded by private investors, including Matt Wullenweg, developer of WordPress, and philanthropist Tim Ferriss. Professor of Law at Harvard Law School.

Policy 52

Policy Law Research and Development Therapy 52

Cannabis Law Report

NOVEMBER 22, 2019

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. MMJ International Holdings is developing oral drug products from natural whole plant extract derivatives from the marijuana plant containing THC and CBD.

DEA 66

DEA Clinical Trials THC Research and Development 66

NORML

MARCH 1, 2019

Currently, the sole federally licensed producer of cannabis for clinical research is the University of Mississippi. ” The agency said that the policy change was necessary because the existing system provided “no clear legal pathway for commercial enterprises to produce marijuana for product development.”

DEA 160

DEA Research and Development Clinical Trials Marijuana 160

Cannabis Law Report

MAY 14, 2022

One of the largest and arguably sustainable customer bases, however, is consumers with some sort of health or therapeutic need for which they are unable to access medicinal cannabis. One potential consequence of the FSA’s drive to rein in the UK’s CBD industry is reduced access to the previously available wide range of products.

Access 52

Access CBD Research and Development Medicine 52

Cannabis Law Report

JULY 9, 2021

The state of the law on psychedelic substances is in flux. Further, numerous private companies have begun to research psychedelic therapy and develop new pharmaceutical compounds derived from psychedelic substances. Some of the most promising substances, and the law applicable to each, are outlined below: Psilocybin.

Law 105

Law Therapy Clinical Trials Research and Development 105

Cannabis Law Report

MAY 12, 2022

Beckley Psytech to collaborate with Lophora on researching New Clinical Entities (NCE’s). Under the terms of the agreement Beckley Psytech will jointly fund continuing development of the Lophora pipeline and collaborate broadly on R&D. May 11, 2022 02:00 AM Eastern Daylight Time.

Medicine 52

Medicine Research and Development Clinical Trials Treatment 52

Cannabis Law Report

AUGUST 10, 2022

Researchers will explore whether the psychoactive effects are necessary to relieve treatment-resistant depression in adults. It’s clear that alternative treatment options are necessary to combat depression and other mental illnesses, which is where companies developing psychedelic-based treatments like Optimi Health Corp.

Clinical Trials 52

Clinical Trials Research and Development Therapy Microdosing 52

Cannabis Law Report

DECEMBER 9, 2021

Nue Life is donating $50,000 to MAPS and $10,000 to the Ketamine Research Foundation. “We believe it is the responsibility of psychedelic-therapy companies to provide material support to the life-changing research being done in the space, which has made our work possible. . MIAMI , Dec. ” About Nue Life.

Research and Development 52

Research and Development Therapy Clinical Trials Treatment 52

Cannabis Law Report

JUNE 7, 2021

ETF, investors also have much easier access to the market. Filament Health partnered with TrPR Psychedelic Research Program at UCSF to advance drug candidates through clinical trials. Industry Developments. PharmaTher and TSRL have teamed up to develop microneedle patches to deliver psychedelics and antivirals.

Research and Development 98

Research and Development Clinical Trials Extraction Retail 98

Cannabis Law Report

JULY 24, 2021

At Mydecine, we are excited to expand our drug development program to include the improvement of entactogenic compounds,” said Rob Roscow, Chief Scientific Officer. “At At Mydecine, we are excited to expand our drug development program to include the improvement of entactogenic compounds,” said Rob Roscow, Chief Scientific Officer.

Research and Development 105

Research and Development Clinical Trials Therapy Events 105

Cannabis Law Report

JUNE 24, 2022

The leader of the New Jersey Senate filed a bill on Thursday that would legalize the possession, home cultivation and gifting of psilocybin mushrooms for adults 21 and older—with provisions that give adults even more freedoms for the psychedelic than are afforded under the state’s current marijuana laws. Full story at.

Clinical Trials 52

Clinical Trials Legalization Research and Development Therapy 52

Cannabis Law Report

AUGUST 12, 2021

Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. Partnership being developed with leading UK institutions to accelerate psychedelic research and develop new models of mental health care in the UK. LONDON, Aug.

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Cannabis Law Report

APRIL 21, 2022

MAPS and MAPS PBC have developed the first validated commercial synthetic process for producing multi-kilogram batches of MDMA under current Good Manufacturing Practices. Publication of this process establishes “prior art,” contributing to MAPS’ patient access strategy by making intellectual property public . The full statement.

Clinical Trials 52

Clinical Trials Research and Development Therapy Media 52

NORML

JANUARY 4, 2019

Steve Cohen (D-TN) and Don Young (R-AK) re-introduced the Compassionate Access, Research Expansion and Respect States (CARERS) Act, which protects those engaged in state-lawful medical marijuana programs from federal prosecution. Legislation is pending, HB 350, to expand medical cannabis access. MA resident? NH resident?

Legislation 124

Legislation Clinical Trials Research and Development Access 124

Cannabis Law Report

SEPTEMBER 8, 2021

Key Transaction Details: The Valens Company, a leading Canadian manufacturer of cannabis products, has entered into a long-term partnership with Epsilon, for exclusive access to the Epsilon’s GMP Manufacturing Facility in Southport , Queensland Australia (the “ Southport Facility ‘).

Access 97

Access Research and Development Medicine THC 97

Cannabis Law Report

SEPTEMBER 22, 2021

Access to Canopy Growth’s cannabinoid library including 335 derivatives and 14 patent families. Accelerated timelines to clinical trials and expansion of drug development pipeline. OCT is also responsible for the manufacture and supply of the compounds for development and commercialisation.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Cannabinoids 52

Cannabis Law Report

JUNE 20, 2021

Patient access. I’ve been working hard with some great advocates for patient access in the UK and this position will give me the opportunity to ensure that patients will have access to the high-quality medicines and products they deserve.”.

Supply Chain 105

Supply Chain Clinical Trials Research and Development Medicine 105

Cannabis Law Report

OCTOBER 2, 2021

MAPS PBC catalyzes healing and well-being through psychedelic drug development, therapist training programs, and sales of prescription psychedelics. We are currently focused on developing MDMA-assisted therapy as a Breakthrough Therapy for PTSD, with plans to submit for FDA approval in 2023. Key Responsibilities.

Clinical Trials 52

Clinical Trials Research and Development Compliance Compliance 52

Cannabis Law Report

APRIL 2, 2022

The partnership draws on Novamind’s expertise delivering psychedelic-assisted psychotherapy and its successful and replicable model for clinics and clinical research sites in the United States. In December 2021, Novamind announced a strategic investment and advisory agreement with Bienstar.

Clinical Trials 52

Clinical Trials Research and Development Medicine Therapy 52

Cannabis Law Report

NOVEMBER 19, 2021

MAPS PBC is pioneering a new form of mental health care, beginning with the development of MDMA-assisted therapy as an FDA-approved treatment for PTSD. We are a diverse team that shares a deep belief in the critical need for innovation and expanded access in the treatment of mental health conditions. Key Responsibilities.

Clinical Trials 52

Clinical Trials Research and Development Therapy Compliance 52

Cannabis Law Report

JUNE 21, 2021

Pharmaceutical companies use artificial intelligence (AI) to sort through reams of scientific data to find potentially effective active ingredients to be developed into approved drugs. But if that doctor has access to information from 40,000 patients it’s a different story. The Upshot.

Data 105

Data Clinical Trials Research and Development Indica 105